Gilead Sciences Inc (GILD)

77.25 -0.29  -0.37% NASDAQ Apr 7, 09:23 Delayed 2m USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
05/06/2020 10:00 PDT Misc Gilead Sciences Inc Annual General Meeting for 2019
05/01/2020 16:30 EDT Misc Gilead Sciences Inc First Quarter Earnings Conference Call in 2020
05/01/2020 Earnings Gilead Sciences Inc First Quarter Earnings in 2020 Release
03/12/2020 Dividends Amount: 0.68, Declared Date: Feb 04 2020, Pay Date: Mar 30 2020
02/25/2020 Misc Gilead Sciences Inc Annual Report for 2019
02/04/2020 16:30 EST Misc Gilead Sciences Inc Fourth Quarter Earnings Conference Call for 2019
02/04/2020 Earnings Gilead Sciences Inc Fourth Quarter Earnings in 2019 Release
12/12/2019 Dividends Amount: 0.63, Declared Date: Oct 24 2019, Pay Date: Dec 30 2019
10/24/2019 16:30 EDT Misc Gilead Sciences Inc Third Quarter Earnings Conference Call for 2019
10/24/2019 Earnings Gilead Sciences Inc Third Quarter Earnings in 2019 Release
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: https://www.gilead.com
  • Investor Relations URL: http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-irhome
  • HQ State/Province: California
  • Sector: Healthcare
  • Industry: Drug Manufacturers - General
  • Equity Style: Large Cap/Value
  • Next Earnings Release: May. 01, 2020
  • Last Earnings Release: Feb. 04, 2020
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: Mar. 12, 2020
  • Description: Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition and pending Forty-Seven acquisition boost Gilead's exposure to cell therapy and non-cell therapy in oncology.

Top Fund Holders

Symbol Name Weighting
IBB iShares Nasdaq Biotechnology ETF 10.58%
XLV Health Care Select Sector SPDR® ETF 3.06%
VHT Vanguard Health Care ETF 2.15%
RMEBX American Funds American Mutual R2E 1.67%
RIBEX American Funds Invmt Co of Amer R2E 1.38%
QQQ Invesco QQQ Trust 1.20%
RAFEX American Funds AMCAP R4 1.17%
IVE iShares S&P 500 Value ETF 1.10%
RCEEX American Funds Capital Income Bldr R2E 0.93%
IWD iShares Russell 1000 Value ETF 0.85%

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.